Tue, January 8, 2019
Mon, January 7, 2019
Fri, January 4, 2019
Thu, January 3, 2019
Wed, January 2, 2019
Mon, December 31, 2018
Fri, December 28, 2018
Thu, December 27, 2018
Wed, December 26, 2018
Fri, December 21, 2018
Thu, December 20, 2018
Wed, December 19, 2018
Tue, December 18, 2018
Mon, December 17, 2018
Fri, December 14, 2018
Thu, December 13, 2018
Wed, December 12, 2018
Tue, December 11, 2018
Mon, December 10, 2018
Fri, December 7, 2018
Thu, December 6, 2018

Matthew Harrison Maintained (VRTX) at Buy with Decreased Target to $210 on, Dec 19th, 2018


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-210-on-dec-19th-2018.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $211 to $210 on, Dec 19th, 2018.

Matthew has made no other calls on VRTX in the last 4 months.



There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Held Target at $220 on, Friday, October 26th, 2018
  • Christopher Raymond of "Raymond James" Maintained at Buy with Decreased Target to $201 on, Thursday, October 25th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018

Publication Contributing Sources